Researchers recently identified XYD270 as a highly potent and selective BRD9 PROTAC cancer therapy for treating aggressive malignancies. This novel degrader specifically targets bromodomain-containing protein 9 (BRD9). Moreover, it acts as a crucial component of the non-canonical BAF (ncBAF) complex. By utilizing proteolysis-targeting chimera (PROTAC) technology, XYD270 effectively hijacks the cellular machinery. Consequently, this approach eliminates oncogenic proteins. This molecule offers a significant advantage over traditional small-molecule inhibitors in treating synovial sarcoma (SS) and acute myeloid leukemia (AML).

Preclinical Efficacy of BRD9 PROTAC Cancer Therapy

In various laboratory models, XYD270 demonstrated exceptional degradation activity. For instance, the molecule achieved a half-maximal degradation concentration (DC50) of 0.082 nM in HS-SY-II cells. Additionally, it showed robust antiproliferative effects in MV4;11 cells with an IC50 of 50 nM. Furthermore, in vivo studies confirmed these results. Specifically, once-daily oral administration of 10 mg/kg in an MV4;11 xenograft model resulted in 54% tumor growth inhibition (TGI). Therefore, these findings suggest that BRD9 degradation is a viable strategy for precision oncology.

The design of XYD270 involved the optimization of diverse cereblon-binding ligands to ensure high selectivity. Consequently, the molecule minimizes off-target effects while maximizing the degradation of the ncBAF complex. Because it is orally bioavailable, XYD270 presents a more convenient treatment option for future clinical applications. Scientists believe that this breakthrough will pave the way for new therapies targeting previously undruggable epigenetic factors.

Frequently Asked Questions

What is the mechanism of action for XYD270?

XYD270 functions as a PROTAC, recruiting an E3 ubiquitin ligase to the BRD9 protein. This process facilitates the ubiquitination and subsequent degradation of BRD9 by the proteasome system within the cell.

Why is BRD9 targeted in synovial sarcoma?

Synovial sarcoma is characterized by a specific fusion oncoprotein that makes the cancer highly dependent on the ncBAF complex. Targeting BRD9 with a BRD9 PROTAC cancer therapy disrupts this essential survival mechanism.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Huang Y et al. Discovery of XYD270 as a Potent, Selective, and Orally Efficacious BRD9 PROTAC for Cancer Therapy. J Med Chem. 2026 Mar 04. doi: 10.1021/acs.jmedchem.5c02858. PMID: 41782172.

National Institutes of Health (NIH). Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms. Published February 2026. Accessed March 2026.